News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Adaptive Biotechnologies Aims for $20 Million Funding Round


7/16/2013 8:22:26 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Seattle startup Adaptive Biotechnologies that makes tools for cancer diagnosis and prognosis is seeking $20 million, according to a regulatory filing. The company has already raised $5 million. A filing from 2012 shows that Adaptive was seeking more than $5 million and ended up raising $2.65 million. Founded in 2009, Adaptive focuses on profiling the immune system. Its flagship product is the immunoSEQ, which the company describes as a "suite of next generation immune sequencing assays that allow researchers to view and analyze the T and B cells of the adaptive immune system with unprecedented depth and specificity."

Help employers find you! Check out all the jobs and post your resume.

Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES